publication . Article . 2011

global issues in drug development for alzheimer s disease

Rachelle S. Doody; Patricia E. Cole; David S. Miller; Eric Siemers; Ronald Black; Howard Feldman; Rachel Schindler; Stephen Graham; Theresa Heath; Ara S. Khachaturian; ...
  • Published: 16 Mar 2011 Journal: Alzheimer's & Dementia, volume 7, pages 197-207 (issn: 1552-5260, Copyright policy)
  • Publisher: Wiley
Abstract The number of clinical trials for Alzheimer's disease conducted outside the United States in a broad array of countries is increasing. As the number of compounds ready for clinical testing increases, and as trials become longer and more complex, this trend is expected to grow. The cultural and ethical context of global clinical trials, potential benefits for those involved, and practical approaches to obstacles generated by these global trials were discussed at a meeting of the Alzheimer's Association Research Roundtable. Regulatory issues, including regional differences in study registration procedures, rules for collecting and reporting serious advers...
free text keywords: Health Policy, Developmental Neuroscience, Epidemiology, Cellular and Molecular Neuroscience, Geriatrics and Gerontology, Psychiatry and Mental health, Clinical Neurology, Audit, Alternative medicine, medicine.medical_specialty, medicine, National identity, Clinical trial, Drug development, Adverse effect, Psychiatry, business.industry, business, Disease
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue